Prostatic Hyperplasia Clinical Trial
Official title:
Observational Sutdy to Assess the Effectiveness of Avodart in Subjects With Benign Prostatic Hyperplasia in Day to Day Clinical Practice
| Verified date | October 2017 |
| Source | GlaxoSmithKline |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.
| Status | Completed |
| Enrollment | 173 |
| Est. completion date | December 19, 2006 |
| Est. primary completion date | December 19, 2006 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia). - Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH. - Patients must only enter the study after the decision to prescribe dutasteride has been undertaken. Exclusion criteria: None specified |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | GSK Investigational Site | Birmingham | |
| United Kingdom | GSK Investigational Site | Bradford | |
| United Kingdom | GSK Investigational Site | Bradford | |
| United Kingdom | GSK Investigational Site | Bristol | |
| United Kingdom | GSK Investigational Site | Colchester | Essex |
| United Kingdom | GSK Investigational Site | East Kilbride | |
| United Kingdom | GSK Investigational Site | Enfield | Middlesex |
| United Kingdom | GSK Investigational Site | Exeter | Devon |
| United Kingdom | GSK Investigational Site | Hull | |
| United Kingdom | GSK Investigational Site | Ilkeston, Derbyshire | |
| United Kingdom | GSK Investigational Site | Leeds | |
| United Kingdom | GSK Investigational Site | Leicester | Leicestershire |
| United Kingdom | GSK Investigational Site | Leytonstone | London |
| United Kingdom | GSK Investigational Site | London | |
| United Kingdom | GSK Investigational Site | London | |
| United Kingdom | GSK Investigational Site | London | |
| United Kingdom | GSK Investigational Site | Manchester | Lancashire |
| United Kingdom | GSK Investigational Site | Manchester | Lancashire |
| United Kingdom | GSK Investigational Site | Nottingham | Nottinghamshire |
| United Kingdom | GSK Investigational Site | Plymouth | Devon |
| United Kingdom | GSK Investigational Site | Sheffield | |
| United Kingdom | GSK Investigational Site | Stevenage | Hertfordshire |
| United Kingdom | GSK Investigational Site | Sunderland | Tyne & Wear |
| United Kingdom | GSK Investigational Site | Sutton Coldfield | West Midlands |
| United Kingdom | GSK Investigational Site | Tauton | Somerset |
| United Kingdom | GSK Investigational Site | Torquay | |
| United Kingdom | GSK Investigational Site | Wakefield |
| Lead Sponsor | Collaborator |
|---|---|
| GlaxoSmithKline |
United Kingdom,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02578953 -
Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects
|
Phase 1 | |
| Terminated |
NCT02396420 -
Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams
|
Phase 2 | |
| Terminated |
NCT04398966 -
Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia
|
N/A | |
| Completed |
NCT02947958 -
Teleconsultation in Counter-reference Between Tertiary and Primary Care for Patients With Benign Prostatic Hyperplasia
|
N/A | |
| Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
| Completed |
NCT00427882 -
Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
|
Phase 4 | |
| Completed |
NCT02244320 -
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
|
N/A | |
| Completed |
NCT01254071 -
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.
|
Phase 1 | |
| Recruiting |
NCT04108871 -
Whether Transperineal Prostate Biopsy Under Local-anaesthesia Using a Transperineal-access System is Non-inferior to Standard Transrectal Biopsy to Detect Prostate Cancer in Biopsy-naïve Men
|
N/A | |
| Recruiting |
NCT05686525 -
Clinical Trial on the Effectiveness of TUMT Compared to PAE in Reducing Severe LUTS in Men With BPH
|
N/A | |
| Completed |
NCT01957189 -
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
|
Phase 1 | |
| Completed |
NCT02715401 -
PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers
|
Phase 1 | |
| Recruiting |
NCT02278679 -
Digital Rectal Exam Proficiency Tool
|
N/A | |
| Completed |
NCT01482676 -
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction
|
N/A | |
| Completed |
NCT01376258 -
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
|
N/A | |
| Completed |
NCT00822952 -
Prostate Mechanical Imager (PMI) Clinical Bridging Study
|
N/A | |
| Completed |
NCT00527605 -
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
| Terminated |
NCT00563654 -
Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
|
N/A | |
| Terminated |
NCT00563485 -
Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
|
N/A | |
| Completed |
NCT00547625 -
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
|
Phase 2 |